Form 4: Integra LifeSciences Executive Harvinder Singh Reports Stock Option and Restricted Stock Unit Awards

EVP & President, International, Harvinder Singh, reports acquisition of stock options and restricted stock units in Integra LifeSciences Holdings Corp.

Summary

• Harvinder Singh, EVP & President, International at Integra LifeSciences Holdings Corp, reported transactions involving non-derivative and derivative securities.
• On March 11, 2024, Singh acquired 16,493 non-qualified stock options with an exercise price of $36.22, vesting in four equal installments annually from the grant date.
• Singh also acquired 7,140 restricted stock units (RSUs) vesting in three installments: 33% on the first and second anniversaries, and 34% on the third anniversary of the grant date.
• Additionally, 16,566 RSUs were acquired, vesting 100% on the second anniversary of the grant date.
• Following these transactions, Singh directly owns 16,493 non-qualified stock options, 21,501 RSUs, and 38,067 RSUs.

Sentiment

Score: 7

Explanation: The sentiment is neutral to slightly positive. The granting of stock options and RSUs is a standard practice and generally viewed as a positive incentive for executives.

Positives

• The granting of stock options and restricted stock units to an executive can be seen as a positive incentive, aligning the executive's interests with those of the shareholders.
• The vesting schedules encourage long-term commitment from the executive.

Future Outlook

The document does not contain specific forward-looking statements, but the vesting schedules of the stock options and RSUs suggest an expectation of continued service from the executive.

Industry Context

Executive compensation through stock options and RSUs is a common practice in the biotechnology and medical device industries to incentivize performance and align executive interests with shareholder value.

Comparison to Industry Standards

• Stock option grants are a standard component of executive compensation packages in publicly traded companies, particularly in the life sciences sector.
• Companies like Stryker, Medtronic, and Boston Scientific also utilize stock options and RSUs to incentivize their executives.
• The vesting schedules described are typical, with vesting periods ranging from two to four years.

Stakeholder Impact

• Shareholders may view the granting of stock options and RSUs as a positive incentive for the executive, potentially leading to increased company performance.
• Employees may see this as a sign of the company's commitment to its leadership.

Key Dates